Study Summary
This trial will test a new targeted cancer treatment in people with a specific type of mesothelioma. The goal is to find the safest dose of the treatment.
Eligible Conditions
- Malignant Pleural Mesothelioma
- Mesothelioma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: 2 years
2 years
MTD of M28z1XXPD1DNR
overall response rate (ORR)
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Engineered Autologous T Cells
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: CAR T cells · No Placebo Group · Phase 1
Engineered Autologous T CellsExperimental Group · 2 Interventions: cyclophosphamide, CAR T cells · Intervention Types: Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
CAR T cells
2017
Completed Phase 2
~30
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Who is running the clinical trial?
Atara BiotherapeuticsIndustry Sponsor
11 Previous Clinical Trials
673 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,508 Total Patients Enrolled
Roisin O'Cearbhaill, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
18 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments